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Abstract
Background: In cystic fibrosis (CF) patients, it has been suggested that systemic inflammation may be an
important risk factor for poor health outcomes. The relationship of plasma inflammatory biomarkers to lung
function and hospitalization history remains largely unexplored.
Methods: This cross-sectional study included 58 consecutive, clinically stable adults from the CF Clinic at St. Paul’s
Hospital (Vancouver, Canada). Blood levels of interleukin (IL)-6, IL-1b, C-reactive protein (CRP), interleukin (IL)-6, IL-
1b, granzyme B (GzmB), chemokine C-C motif ligand 18 (CCL18/PARC), surfactant protein D (SP-D),
lipopolysaccharide (LPS)-binding protein, and soluble cluster of differentiation 14 (sCD14) were measured using
enzyme-linked immunosorbent assays, and LPS levels were measured using a Limulus amebocyte lysate assay.
Spirometry was also performed. Multivariable linear regression analysis was used to assess relationships of the
blood biomarkers to lung function.
Results: Lung function impairment was independently associated with elevated plasma levels of CRP (P < 0.01), IL-
6( P = 0.04), IL-1b (P < 0.01), and LBP (P < 0.01). Increasing age (P < 0.01), reduced body mass index (P = 0.02),
prior hospitalizations (P = 0.03), and presence of Pseudomonas aeruginosa in sputum cultures (P < 0.01) were also
associated with reduced lung function. Elevated concentrations of LPS in plasma were associated with a previous
history of hospitalization (P < 0.05). There was a trend towards an increase in plasma IL-6 (P = 0.07) and IL-1b (P =
0.06) levels in patients who were previously hospitalized.
Conclusions: IL-6 and IL-1b are promising systemic biomarkers for lung function impairment and history of
hospitalization in adult patients with CF.
Background
Cystic fibrosis (CF) is a progressive, debilitating disease
that affects nearly 30,000 Americans and occurs with a
frequency of about 1 in 3500 births [1]. It is character-
ized by persistent lung infection and lung function
impairment. It also affects other organs including the
sinuses, gastrointestinal tract, endocrine glands, and the
bone [2-5]. Although all CF cases are caused by a muta-
tion in the gene for the CF transmembrane conductance
regulator, there is considerable heterogeneity in the rate
at which the disease progresses [6]. The traditional risk
factors for rapid progression include reduced body mass
index, colonization of the airways with pathogenic bac-
teria such as Pseudomonas aeruginosa,a n df e m a l es e x
[7-9]. More recently, some have suggested that systemic
inflammation may be another important risk factor for
poor health outcomes in CF independent of these tradi-
tional risk factors [3,8,10,11]. However, the studies that
have evaluated this issue have produced inconsistent
results and have measured different components of the
immune system, making cross comparisons difficult.
Moreover, none of these studies have evaluated these
biomarkers on hard clinical outcomes such as exacerba-
tions or hospitalizations, which are important endpoints
in CF. In this study, we determined the relationship of
plasma inflammatory biomarkers to lung function and
hospitalization history in adult patients with CF. The
plasma biomarkers were carefully chosen to represent
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negative pathogens, or lung-based proteins.
Methods
Study Population and Blood Collection
We enrolled 58 consecutive adult patients from the Cys-
tic Fibrosis (CF) Clinic at St. Paul’s Hospital (Vancouver,
British Columbia, Canada) between April and December
2009, who were clinically stable at the time of assess-
ment. For inclusion, patients had to have one or more
clinical features consistent with the CF phenotype [12]
as well as a genotype with two identifiable disease-caus-
ing CF transmembrane conductance regulator (CFTR)
mutations and sweat chloride measurements greater
than 60 mmol/L on two occasions. Patients who had an
exacerbation within the previous 4 weeks were excluded
from the study. This study was conducted with the
approval of the University of British Columbia - Provi-
d e n c eH e a l t hC a r eR e s e a r c hE t h i c sB o a r d( U B C - P H C
REB). Following informed consent, we collected venous
blood samples and performed spirometry using standard
techniques, in accordance with guidelines from the
American Thoracic Society [13]. Demographic and clini-
cal data were obtained by chart review.
Clinical Information
The subjects’ infection status was determined by micro-
bial review within the preceding 3 years of study entry.
Those who had at least one sputum culture positive of
Pseudomonas aeruginosa were considered to be infected
by this organism. We also performed chart review and
retrieved data from the hospital database to determine
whether the patients had a hospitalization for CF
exacerbation in the previous 5 years.
Biomarker Assays
Plasma was prepared from the collected blood samples
and a select number of circulating inflammatory pro-
teins were measured using high-sensitivity enzyme-
linked immunosorbent assay (ELISA) kits that were
commercially available. These included interleukin (IL)-
6a n dI L - 1 b (R&D Systems, Minneapolis, MN), cyto-
kines involved in the early phase inflammatory response;
C-reactive protein (CRP; R&D Systems), an acute phase
response protein; granzyme B (GzmB; eBioscience, San
Diego, CA), a protein involved in adaptive immunity;
chemokine C-C motif ligand 18/pulmonary and activa-
tion-regulated chemokine (CCL18/PARC; R&D Systems)
and surfactant protein D (SP-D; Biovendor, Brno, Czech
Republic), pneumo-proteins (i.e. proteins synthesized
predominantly in the lungs) [14,15]; and LPS-binding
protein (LBP; Hycult Biotech, Uden, The Netherlands)
and soluble cluster of differentiation 14 (sCD14; R&D
Systems), proteins involved in lipopolysaccharide (LPS)
signalling. The coefficients of variation for these kits
were 7.4%, 12.3%, 3.1%, 5.8%, 1.2%, 2.2%, 1.7%, and 5.9%
respectively, and the lower detection limits were 0.039
pg/mL, 0.057 pg/mL, 0.010 ng/mL, 0.2 pg/mL, 0.01 ng/
mL, and 0.2 ng/mL, 4.4 ng/mL, and 0.125 ng/mL
respectively. LPS levels were measured using a commer-
cially-available kinetic chromogenic Limulus amebocyte
lysate (LAL) assay kit (Lonza Walkersville, Walkersville,
MD) following plasma dilution and heat inactivation
pre-treatment steps to diminish interference from
plasma proteins. The coefficient of variation for the
assay was 2.2%, and the lower detection limit was 0.5
pg/mL. Of these biomarker assays, only the IL-1b ELISA
had samples with values below the limit of detection (18
undetectable out of 58 samples, or 31%). In plasma sam-
ples, the manufacturers’ reported ranges for IL-6, IL-1b,
CRP, GzmB, and sCD14 measurements in healthy
volunteers were 0.428 to 8.8 pg/mL, non-detectable to
0.452 pg/mL, 104 to 4185 ng/mL, 0.8 to 24.1 pg/mL,
and 1200 to 3100 ng/mL, respectively. Reference ranges
were not available for CCL18/PARC, SP-D, LBP, and
LPS, and the dynamic ranges of these assays were 7.8 to
500 pg/mL, 1.56 to 100 ng/mL, 4.4 to 50 ng/mL, and
0.5 to 500 pg/mL, respectively.
Statistical Analysis
Data for the biomarker measurements were analyzed
after natural log transformation due to their skewed
distribution, and values below the limit of detection
were assigned the value of the lower detection limit for
the particular kit. The relationships of the biomarkers
to lung function (FEV1 as a percentage of predicted)
and to each other were assessed using linear regres-
sion. Multivariable linear regression analysis was per-
formed to assess the role of possible confounding
factors such as age, sex, and pseudomonal status.
Plasma biomarker levels were compared between those
who did and did not experience a hospitalization in
t h ep a s tu s i n gaS t u d e n t ’s t- t e s tf o ri n d e p e n d e n ts a m -
ples. Fisher’s exact test was used to analyze categorical
data. The independent relationship of plasma biomar-
kers to FEV1% predicted was ascertained using multiple
regression analysis. To ensure parsimony and enhance
the robustness of the model, we used a stepwise
approach to select only those covariates that signifi-
cantly impacted on the relationship (the significance
level for entering, P ≤ 0.05 and the significance level
for stay, P ≤ 0.05). To facilitate interpretation and
cross-comparisons of beta-coefficients of plasma bio-
markers from the regression model, we standardized
the beta-coefficients to their standard deviation. Thus,
the beta-coefficients are presented per 1 SD increase in
the plasma biomarker expression. P-values less than
0.05 were considered significant (two-tailed test). All
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sion 9.1.
Results
Patient Demographics
The age of the study subjects ranged from 18 to 61
years (Table 1). The baseline clinical characteristics of
the study subjects are summarized in Table 1 in two
groups based on the median value of FEV1% predicted.
Greater mean age, reduced BMI, hospitalizations in the
previous 5 years, and presence of Pseudomonas aerugi-
nosa in sputum cultures were all significantly asso-
ciated with below-median FEV1% predicted values. Of
the 58 subjects, 21 had been hospitalized (36% of total)
and 37 had not. 42 of the subjects were classified as
Pseudomonas+ based on sputum microbiology (72.41%
of total) and 16 were Pseudomonas-. A greater portion
of patients with below-median FEV1% predicted values
had been administered Azithromycin and Tobramycin
versus patients with above-median FEV1% predicted
values.
Systemic Inflammation and Lung Function
CRP, IL-6, IL-1b, and LBP were significantly correlated
with lung function impairment in both univariable and
multivariable analysis (Table 2). LPS was significantly
related to FEV1 only in the multivariable analysis. The
use of standardized beta-coefficient (i.e. the change in
FEV1% predicted per 1 standard deviation increase in
the plasma concentrations of the biomarker) allows for
comparison of the beta-coefficients across biomarkers.
CRP had the highest standardized beta-coefficient,
followed by LBP, IL-6 and IL-1b, suggesting that CRP is
most strongly associated with FEV1. Geometric mean
plasma levels of IL-6, IL-1b,C R P ,a n dL B Po fp a t i e n t s
with below-median FEV1% predicted values were 3.0 pg/
m L ,0 . 2 1p g / m L ,4 . 6μg/mL, and 33.2 μg/mL, respec-
tively. These were all significantly higher than in
patients with above-median FEV1% predicted values (1.6
pg/mL, 0.12 pg/mL, 2.0 μg/mL, and 22.9 μg/mL, respec-
tively) (Figure 1). The geometric mean plasma level of
GzmB was significantly lower in patients with below-
median FEV1% predicted values (71.6 pg/mL) compared
to those with above-median FEV1% predicted values
(166.3 pg/mL).
Circulating Systemic Inflammatory Biomarkers and
Hospitalization History
The geometric mean plasma levels of IL-6, IL-1b,a n d
LPS of hospitalized CF subjects were 3.6 pg/mL, 0.19
pg/mL, and 1.3 ng/mL, respectively. These were all sig-
nificantly higher than in non-hospitalized subjects (1.7
pg/mL, 0.10 pg/mL, and 0.97 ng/mL, respectively)
(Table 3). After adjustment for FEV1% predicted, BMI
and pseudomonal status in sputum, the relationships
weakened (Table 3). There was a significant association
between plasma IL-6 levels and IL-1b levels (Figure 2).
Geometric mean plasma concentrations of CRP, GzmB,
CCL18, SP-D, LBP, and sCD14 did not significantly dif-
fer between the previously hospitalized and non-hospita-
lized groups (Table 3). The c-statistic of FEV1, BMI and
pseudomonal status together was 0.797. There was a
modest improvement in the c-statistic by adding IL-6,
IL-1b, or LPS (0.837, 0.828, and 0.841, respectively).
Table 1 Patient demographics and clinical characteristics
Total
(n = 58)
FEV1% predicted
≥ median
(n = 29)
FEV1% predicted
< median
(n = 29)
P-value
Age, years range 18 - 61 18 - 49 19 - 61 < 0.01
Sex, male n (%) 34 (58.62) 18 (62.1) 16 (55.2) 0.79
BMI, kg/m
2 ± SD 23.24 ± 3.25 24.2 ± 3.4 22.3 ± 2.9 0.02
FEV1, % predicted ± SD 71.93 ± 24.80 92.9 ± 12.9 51.0 ± 13.2 -
Current medications
Azithromycin, n (%) 18 (31.03) 3 (10.3) 15 (51.7) < 0.01
Ciprofloxacin, n (%) 2 (3.45) 1 (3.4) 1 (3.4) 1.00
Dornase alfa, n (%) 24 (41.38) 11 (37.9) 13 (44.8) 0.79
Ibuprofen, n (%) 2 (3.45) 2 (6.9) 0 (0) 0.49
Prednisone, n (%) 0 (0) 0 (0) 0 (0) -
Tobramycin, n (%) 13 (22.41) 2 (6.9) 11 (37.9) 0.01
Inhaled steroids, n (%) 37 (63.79) 15 (51.7) 22 (75.9) 0.10
Diabetes, n (%) 22 (37.93) 10 (34.5) 12 (41.4) 0.79
Hospitalization, n (%) 21 (36.2) 6 (20.7) 15 (51.7) 0.03
Pseudomonas, n (%) 42 (72.41) 15 (51.7) 27 (93.1) < 0.01
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This was a unique study investigating the relationship of
systemic inflammation to lung function impairment and
hospitalization history among clinically stable CF
patients. This study produced several important find-
ings. First, biomarkers that are related to innate immu-
nity or early acute phase reactants such as IL-6, IL-1b,
CRP, and LBP were significantly associated with reduced
lung function in CF patients independent of age, pseu-
domonal status, or history of hospitalization, suggesting
that systemic inflammation is an independent risk factor
for disease progression in CF. The directionality of the
relationship is uncertain. Thus, it remains unknown
whether the rise in these biomarkers is the result or the
cause of impaired lung function. Our data extend the
findings of a previous study that examined a cohort of
adult CF patients aged 30 years or greater. Levy et al.
found an association between lower FEV1 percent pre-
dicted and higher serum CRP levels, but they did not
adjust for sex or pseudomonal status of the patients,
and the study cohort was limited to an older population
[11]. Furthermore, their retrospective study design pre-
vented them from obtaining serum samples and per-
forming pulmonary function tests within a close
proximity of time. While our current study did not
make comparisons to healthy controls, previous studies
have found that median plasma or serum concentrations
of IL-6, IL-1b, IL-1 receptor antagonist (IRAP) [16],
neutrophil granule proteins, and CRP [17] were higher
in CF patients versus healthy subjects. Collectively, the
use of plasma markers of systemic inflammation, espe-
cially IL-6 and CRP, provides additional indicators of
clinical status and may add to our understanding of the
relationship between inflammation and the severity of
lung disease in CF patients.
Second, in addition to the traditional factors such as
reduced BMI, poor lung function as measured by FEV1
percent predicted, and presence of Pseudomonas aerugi-
nosa in sputum cultures, we found that plasma levels of
two early phase inflammatory cytokines, IL-6 and IL-1b,
were significantly associated with prior hospitalization in
patients with CF, independent of the traditional factors.
However, there was no significant relationship of GzmB,
a marker of adaptive immunity, lung-based proteins
such as CCL18/PARC and SP-D, or acute-phase reac-
tants such as CRP, LBP, and sCD14 [18] with hospitali-
zation history. Together, these data suggest that early
phase inflammatory cytokines may be good candidate
plasma biomarkers of health outcomes in CF.
Our third important finding was that plasma LPS
derived from Gram-negative bacteria is significantly
higher in those who were previously hospitalized for a
CF exacerbation than those who were not. LPS is an
immunologically active antigen, which can cause an
intense inflammatory process in the lung and elsewhere.
Its presence in the systemic circulation may enhance the
systemic inflammatory response in CF, as previously
seen in a murine model [19]. We postulate that some of
the LPS expression in the systemic circulation may be
derived from the lungs through a process called translo-
cation. It is conceivable that the diseased respiratory
tract in CF may facilitate translocation of bacterial com-
ponents or pro-inflammatory cytokines from the lungs
to the systemic circulation where it incites an inflamma-
tory response. This biological plausibility is supported
by a study in rabbits where it was shown that it is physi-
cally possible for LPS to undergo pulmonary-to-systemic
translocation under certain conditions, specifically in
mechanical ventilation strategies [20]. While our meth-
ods did not allow us to determine the originating source
of plasma LPS, we speculate that the LPS we measured
is likely derived from P. aeruginosa in the lungs or other
Gram-negative, CF-related bacteria. Future studies will
be needed to test this hypothesis.
Table 2 Relationship between FEV1 percent predicted and biomarkers in CF subjects per 1 log increase in the
biomarkers (n = 58)
Unadjusted Adjusted* Standardized Beta-Coefficient
(per 1 SD increase in the levels of biomarker)
Biomarker b ±S E P-value b ±S E P-value
CRP, mg/L -10.61 ± 2.65 < 0.01 -7.04 ± 1.98 < 0.01 -0.3134
IL-6, pg/mL -10.72 ± 3.11 < 0.01 -5.53 ± 2.66 0.04 -0.2159
IL-1b, pg/mL -6.97 ± 3.36 0.04 -4.65 ± 2.67 < 0.01 -0.1784
SP-D, μg/mL -17.70 ± 7.95 0.03 -9.83 ± 5.93 0.10 -0.1584
CCL18, pg/mL -6.33 ± 5.93 0.29 -3.01 ± 4.23 0.48 -0.0672
GzmB, pg/mL 4.09 ± 2.27 0.08 -0.33 ± 1.89 0.86 -0.0187
LPS, pg/mL 1.07 ± 7.44 0.89 13.30 ± 5.41 0.02 0.0239
sCD14, μg/mL 1.88 ± 9.67 0.85 -10.26 ± 6.96 0.15 -0.1414
LBP, μg/mL -22.28 ± 6.63 < 0.01 -16.02 ± 4.74 < 0.01 -0.2946
* Adjusted for age, pseudomonal status, and history of hospitalization, which were significantly related to reduced lung function
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Page 4 of 7Figure 1 Plasma biomarker concentrations in cystic fibrosis subjects with above-median (n = 29) and below-median (n = 29) FEV1%
predicted values. (A-D) Geometric mean plasma levels of IL-6, IL-1b, CRP, and LBP were higher in subjects with below-median FEV1% predicted
values than in those with above-median FEV1% predicted values. (E) The geometric mean plasma level of GzmB was lower in subjects with
below-median FEV1% predicted values than in those with above-median FEV1% predicted values.
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a cross-sectional study, which precludes firm conclu-
sions on causality or directionality of the relationship.
While we postulate that systemic inflammation drives
disease progression, it is entirely possible that disease
progression is responsible for systemic inflammation,
and a comprehensive prospective longitudinal study
would be needed to address this issue. Longitudinal data
may also provide insight into plasma biomarker profiles
during acute exacerbations and following antibiotic
treatment. Additionally, we did not measure other pro-
inflammatory biomarkers such as TNF-a and IL-8 or
those with known anti-inflammatory effects such as IL-
10, which has been shown in a mouse model to reduce
the inflammatory response to Pseudomonas aeruginosa
[21]. Future investigation into these regulators of the
inflammatory response could provide a clearer picture
of the complex interactions involved that lead from
excessive inflammation to disease progression.
Conclusions
Notwithstanding the limitations, we found that more
intense systemic inflammation, mediated by the innate
immune system, is associated with prior CF hospitaliza-
tions and with lung function impairment in CF. IL-6
and IL-1b, in particular, are promising systemic biomar-
kers for disease progression and hospitalization in CF. A
large prospective study testing these promising biomar-
kers would be of great value in determining their useful-
ness as a clinical tool in managing patients with CF.
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